Cost-effectiveness of fondaparinux versus enoxaparin in the prevention of venous thromboembolism following major orthopedic surgery in Austria;Kosteneffektivität von fondaparinux versus enoxaparin in der prävention von venösen thromboembolien nach größeren orthopädischen eingriffen in österreich

Perfusion

Volumn 17, Issue 1, 2004, Pages 4-14

  Rieder, Anita ^a   Dorner, Thomas ^a   Kunze, Michael ^a   Reiter, Martina ^b   Nanz, Sylvia ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Sanofi Synthelabo GmbH Wien   (Austria)

Author keywords

Austria; Cost effectiveness; Enoxaparin; Fondaparinux; VTE

Indexed keywords

EID: 24344476062     PISSN: 09350020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158(6):585-593
2. Statistik Austria (Hrsg.): Jahrbuch der Gesundheitsstatistik. Wien, 2003
3. Gallus AS. Applying risk assessment models in orthopaedic surgery: overview of our clinical experience. Review. Blood Coagul Fibrinol 1999;10 Suppl 2:S53-S61
4. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S
5. Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med. 1999;159(1):1-14
6. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162(16):1833-1840
7. Bergqvist D. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics 2002;20(4):225-43.
8. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery. JAMA 1987;257:203-208
9. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304
10. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip replacement surgery: a randomized double-blind comparison. Lancet 2002;359:1715-1720
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310
12. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin. Arch Intern Med 1998;158:873-878
13. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81A:932-940
14. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376
15. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
16. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-1531
17. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med 2000;160:769-774
18. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7
19. Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet 2002;359:1721-1726
20. Verordnung der Wiener Landesregierung über die Festsetzung der Ambulatoriumsbeiträge für die Wiener Städtischen Krankenanstalten. Landesgesetzblatt für Wien, Jahrgang 2001, ausgegeben am 7. Dezember 2001, 102. Stück; 102. Verordnung
21. Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost 2003;1(5):896-906
22. Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am J Orthop 2003;32(4):201-205
23. Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2001;86(1):475-87
24. Sullivan S, Davidson B. Kahn S, et al. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing major orthopedic surgery. Abstracts of the 44th Annual Meeting of the American Society of Hematology (ASH), Philadelphia, Pennsylvania, USA, 6-10 December 2002
25. Annmans L, De Groot K. Cost-effectiveness of fondaparinux (Arixtra) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1(Suppl):P2053
26. Gordois A, Posnett J. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003;1(10):2167-2174